Clinical Trial: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07431177) titled 'A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo' on Feb. 18.

Brief Summary: The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Non-segmental Vitiligo

Intervention: DRUG: GIA632

GIA632 will be administered during the 48-week core period.

DRUG: Placebo

Placebo will be administered duri...